Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment

  • Published : 2023.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol 2021;77: 1439-50. https://doi.org/10.1016/j.jacc.2021.01.027
  2. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol 2019;4:1287-95. https://doi.org/10.1001/jamacardio.2019.3780
  3. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337-45. https://doi.org/10.1161/CIRCOUTCOMES.110.959247
  4. Sniderman AD. ApoB vs non-HDL-C vs LDL-C as markers of cardiovascular disease. Clin Chem 2021;67:1440-2. https://doi.org/10.1093/clinchem/hvab140
  5. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2019;73:3168-209. https://doi.org/10.1016/j.jacc.2018.11.002
  6. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41: 111-88. https://doi.org/10.1093/eurheartj/ehz455
  7. Verbeek R, Hovingh GK, Boekholdt SM. Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol 2015;26:502-10. https://doi.org/10.1097/MOL.0000000000000237
  8. Emerging Risk Factors Collaboration; Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000. https://doi.org/10.1001/jama.2009.1619
  9. Emerging Risk Factors Collaboration; Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-506.
  10. Yun SY RJ, Kang H, Lee SG, Lim JB. Associations of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B with cardiovascular disease occurrence in adults: Korean Genome and Epidemiology Study. Ann Lab Med 2023;43:237-47. https://doi.org/10.3343/alm.2023.43.3.237
  11. Cantey EP and Wilkins JT. Discordance between lipoprotein particle number and cholesterol content: an update. Curr Opin Endocrinol Diabetes Obes 2018;25:130-6. https://doi.org/10.1097/MED.0000000000000389
  12. Yang HS, Hur M, Kim H, Kim SJ, Shin S, Di Somma S, et al. HDL subclass analysis in predicting metabolic syndrome in Koreans with high HDL cholesterol levels. Ann Lab Med 2020;40:297-305. https://doi.org/10.3343/alm.2020.40.4.297
  13. Yang HS, Jeong HJ, Kim H, Hwang HK, Hur M, Lee S. Sex-specific Ushaped relationships between high-density lipoprotein cholesterol levels and 10-year major adverse cardiovascular events: a nationwide cohort study of 5.7 million South Koreans. Ann Lab Med 2022;42:415-27. https://doi.org/10.3343/alm.2022.42.4.415